scholarly journals Association of body mass index with mortality and postoperative survival in renal cell cancer patients, a meta-analysis

Oncotarget ◽  
2018 ◽  
Vol 9 (17) ◽  
pp. 13959-13970 ◽  
Author(s):  
Jiao Zhang ◽  
Qiang Chen ◽  
Zhan-Ming Li ◽  
Xu-Dong Xu ◽  
Ai-Fang Song ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Meta Analysis ◽  
Cell Cancer ◽  
Postoperative Survival

scholarly journals Body Mass Index and Renal Cell Cancer

Epidemiology ◽  
2012 ◽  
Vol 23 (6) ◽  
pp. 821-828 ◽  
Author(s):  
Jennifer L. Beebe-Dimmer ◽  
Joanne S. Colt ◽  
Julie J. Ruterbusch ◽  
Gregory R. Keele ◽  
Mark P. Purdue ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer

scholarly journals Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

2019 ◽  
Vol 25 (13) ◽  
pp. 3839-3846 ◽  
Author(s):  
Ugo De Giorgi ◽  
Giuseppe Procopio ◽  
Diana Giannarelli ◽  
Roberto Sabbatini ◽  
Alessandra Bearz ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Systemic Inflammation ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer

Influence of Body Mass Index and Smoking on the Long-Term Survival of Patients With Renal Cell Cancer

2013 ◽  
Vol 11 (4) ◽  
pp. 458-464 ◽  
Author(s):  
Kaisa Leea Sunela ◽  
Matti Jorma Kataja ◽  
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Term Survival ◽  
Long Term Survival

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

Sign in / Sign up

Export Citation Format

Share Document